Published in Breast Cancer Res Treat on July 08, 2014
Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol (2015) 0.82
Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther (2015) 0.80
ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. J Transl Med (2014) 0.78
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget (2016) 0.77
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther (2017) 0.76
The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett (2016) 0.76
Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment. Medicine (Baltimore) (2015) 0.75
Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. Mol Clin Oncol (2015) 0.75
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth. Oncogenesis (2016) 0.75
Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. Exp Ther Med (2015) 0.75
Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. Breast Care (Basel) (2017) 0.75
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
Adjuvant trastuzumab for breast cancer. BMJ (2005) 2.98
Primary care physicians' views of routine follow-up care of cancer survivors. J Clin Oncol (2009) 2.77
The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer (2005) 2.69
Spontaneous talking time at start of consultation in outpatient clinic: cohort study. BMJ (2002) 2.61
Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer (2008) 2.53
Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst (2003) 2.51
Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: insight from a randomized trial. Circulation (2007) 2.39
Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension (2009) 2.34
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer (2009) 2.29
Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol (2008) 2.24
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol (2005) 2.20
Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J (2004) 2.18
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol (2009) 2.04
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res (2012) 1.81
Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol (2004) 1.80
In vivo 3D high-spatial-resolution MR imaging of intraplaque hemorrhage. Radiology (2008) 1.74
The effect of tracheostomy timing during critical illness on long-term survival. Crit Care Med (2008) 1.66
Palliative treatment of painful bone metastases with MR imaging--guided focused ultrasound. Radiology (2008) 1.64
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer. Clin Cancer Res (2010) 1.63
Subcutaneous adipose tissue zinc-α2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. Obesity (Silver Spring) (2014) 1.56
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res (2010) 1.56
Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens (2009) 1.56
Impact of job and marital strain on ambulatory blood pressure results from the double exposure study. Am J Hypertens (2005) 1.48
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol (2006) 1.47
Anthracyclines in early-stage breast cancer: is it the end of an era? Oncologist (2009) 1.46
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer (2006) 1.45
Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer (2010) 1.44
Targeted temperature management processes and outcomes after out-of-hospital cardiac arrest: an observational cohort study*. Crit Care Med (2014) 1.43
Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol (2005) 1.43
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist (2010) 1.42
Pain & comfort: the pathophysiology of pain & prehospital treatment options. JEMS (2003) 1.39
Mnemonics in dermatology. Int J Dermatol (2006) 1.39
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev (2011) 1.39
The use of complementary and alternative medicines among patients with locally advanced breast cancer--a descriptive study. BMC Cancer (2006) 1.30
Comorbidities in chronic neuropathic pain. Pain Med (2004) 1.28
Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol (2007) 1.27
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat (2009) 1.25
High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. J Clin Oncol (2009) 1.22
Tracheostomy timing in traumatic brain injury: a propensity-matched cohort study. J Trauma Acute Care Surg (2014) 1.22
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist (2010) 1.22
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev (2012) 1.21
Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther (2007) 1.20
Receiving the diagnosis of lung cancer: patient recall of information and satisfaction with physician communication. J Clin Oncol (2008) 1.18
A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manage (2009) 1.18
Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat (2010) 1.18
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol (2009) 1.16
A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage (2010) 1.15
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2007) 1.13
Keeping faith with trial volunteers. Nature (2007) 1.13
Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time? Support Care Cancer (2014) 1.12
Negative regulation of corticotropin releasing factor expression and limitation of stress response. Stress (2007) 1.09
Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat (2005) 1.08
External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. BMC Cancer (2007) 1.08
Optimum frequency of office blood pressure measurement using an automated sphygmomanometer. Blood Press Monit (2008) 1.08
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res (2013) 1.08
Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol (2004) 1.07
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer (2008) 1.07
Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manage (2009) 1.06
Effects of benzodiazepines receptor agonists on the hypothalamic-pituitary-adrenocortical axis. Eur J Pharmacol (2005) 1.05
Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol (2009) 1.05
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol (2013) 1.05
Intensive care outcomes in bone marrow transplant recipients: a population-based cohort analysis. Crit Care (2008) 1.04
Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer (2004) 1.04
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol (2006) 1.03
Clinician accuracy when estimating survival duration: the role of the patient's performance status and time-based prognostic categories. J Pain Symptom Manage (2011) 1.02
The conventional versus automated measurement of blood pressure in the office (CAMBO) trial: masked hypertension sub-study. J Hypertens (2012) 1.01
Consistent relationship between automated office blood pressure recorded in different settings. Blood Press Monit (2009) 1.01
Oncology education in Canadian undergraduate and postgraduate training programs. J Cancer Educ (2009) 1.00
Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy. Transl Oncol (2012) 1.00
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J Thorac Oncol (2013) 1.00
Intracranial pressure monitoring in severe traumatic brain injury: results from the American College of Surgeons Trauma Quality Improvement Program. J Neurotrauma (2013) 0.99
CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol (2011) 0.99
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer (2008) 0.99
Prenatal immune challenge affects growth, behavior, and brain dopamine in offspring. Ann N Y Acad Sci (2004) 0.99
Adjuvant targeted therapy in early breast cancer. Cancer (2009) 0.99
Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study. BMC Cancer (2013) 0.99
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer (2012) 0.99
The impact of major depression on outcome following mild-to-moderate traumatic brain injury in older adults. J Affect Disord (2006) 0.98